<DOC>
	<DOC>NCT01665352</DOC>
	<brief_summary>The purpose of this study is to compare the safety and effect of TTP054 versus placebo on glucose control in patients with type 2 diabetes.</brief_summary>
	<brief_title>A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Diagnosis of type 2 diabetes mellitus On a stable (for the last 3 months) regimen of either metformin alone or metformin in combination with one additional acceptable oral antidiabetic (OAD) agent HbA1c: Metformin only: 7.0 11.0%; Metformin + acceptable OAD agent: 6.5 9.5% History or evidence of significant diabetic complications History of heart attack, stroke or congestive heart failure Severe, uncontrolled hypertension Frequent hypoglycemia Women of childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>